Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tretinoin
Drug ID BADD_D02270
Description Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of vitamin A (retinol). Retinoids such as tretinoin are important regulators of cell reproduction, proliferation, and differentiation and are used to treat acne and photodamaged skin and to manage keratinization disorders such as ichthyosis and keratosis follicularis. Tretinoin also represents the class of anticancer drugs called differentiating agents and is used in the treatment of acute promyelocytic leukemia (APL).
Indications and Usage For the the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant); For the topical treatment of acne vulgaris, flat warts and other skin conditions (psoriasis, ichthyosis congenita, icthyosis vulgaris, lamellar icthyosis, keratosis palmaris et plantaris, epidermolytic hyperkeratosis, senile comedones, senile keratosis, keratosis follicularis (Darier's disease), and basal cell carcinomas.); For palliative therapy to improve fine wrinkling, mottled hyperpigmentation, roughness associated with photodamage.
Marketing Status Prescription; Discontinued
ATC Code D10AD01; L01XF01
DrugBank ID DB00755
KEGG ID D00094
MeSH ID D014212
PubChem ID 444795
TTD Drug ID D02DGU
NDC Product Code 0378-8093; 48943-0011; 0378-8090; 17337-0045; 0378-6140; 62032-417; 79572-030; 10370-268; 53002-8100; 62032-413; 0187-5162; 0378-8082; 68634-069; 0574-2201; 13548-070; 63629-8752; 0574-2205; 16714-249; 62032-414; 68682-513; 0187-5170; 50090-0651; 0378-8084; 0187-0005; 51672-1394; 63629-2285; 51927-1270; 0378-8083; 62032-412; 70518-3233; 55361-0028; 0187-5150; 64566-0009; 70518-3223; 68682-514; 0574-2301; 49452-6243; 16714-250; 0187-5146; 0187-5140; 0574-2225; 42291-870; 50090-3058; 0187-5160; 0187-5172; 53002-8101; 71052-401; 0378-8092; 68462-792; 0187-5164; 51552-0120; 38779-0001; 62049-003; 0555-0808; 17337-0036; 0904-6867; 0378-6141; 0378-8086; 68084-075; 62991-2057; 0187-5148; 51672-1395; 50090-4347; 76055-0007; 50090-3128; 42291-843; 0187-5144; 50090-4486; 0472-0117; 0378-8085; 0574-2325; 68682-800; 76420-159
Synonyms Tretinoin | Retinoic Acid | Acid, Retinoic | Vitamin A Acid | Acid, Vitamin A | all-trans-Retinoic Acid | Acid, all-trans-Retinoic | all trans Retinoic Acid | trans-Retinoic Acid | Acid, trans-Retinoic | trans Retinoic Acid | Retin-A | Retin A | Tretinoin Potassium Salt | Potassium Salt, Tretinoin | Salt, Tretinoin Potassium | Tretinoin Zinc Salt | Salt, Tretinoin Zinc | Zinc Salt, Tretinoin | Vesanoid | beta-all-trans-Retinoic Acid | Acid, beta-all-trans-Retinoic | beta all trans Retinoic Acid | Tretinoin Sodium Salt | Salt, Tretinoin Sodium | Sodium Salt, Tretinoin
Chemical Information
Molecular Formula C20H28O2
CAS Registry Number 302-79-4
SMILES CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Acidosis14.01.03.002--
Acne23.02.01.0010.000520%Not Available
Acute febrile neutrophilic dermatosis23.03.03.033; 01.02.01.0060.000520%Not Available
Acute myeloid leukaemia16.01.05.001; 01.10.05.0010.000204%Not Available
Acute promyelocytic leukaemia01.10.05.003; 16.01.05.0030.000520%Not Available
Acute respiratory failure22.02.06.001; 14.01.04.0040.000136%Not Available
Agitation19.06.02.001; 17.02.05.012--
Alopecia23.02.02.0010.000520%
Anxiety19.06.02.0020.001040%
Aphasia19.21.01.001; 17.02.03.0010.000520%
Application site erythema12.07.01.001; 08.02.01.001; 23.03.06.005--Not Available
Application site oedema12.07.01.020; 08.02.01.020--Not Available
Application site pain12.07.01.004; 08.02.01.004--Not Available
Application site pruritus23.03.12.004; 12.07.01.005; 08.02.01.005--Not Available
Application site rash23.03.13.008; 12.07.01.016; 08.02.01.016--Not Available
Arrhythmia02.03.02.001--Not Available
Arthralgia15.01.02.001--
Ascites07.07.01.001; 09.01.05.003; 02.05.04.002--
Asterixis17.01.06.001; 09.01.03.004--Not Available
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Atrioventricular block complete02.03.01.0030.000520%
Auditory disorder04.02.03.002--Not Available
Back pain15.03.04.0050.000520%
Basophilia01.02.01.009--Not Available
Benign intracranial hypertension17.07.02.0010.002601%Not Available
Bladder pain20.02.02.001--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 11 Pages